Ads
related to: Renal Cell Carcinoma- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- Clinical Trial Info
Review Clinical Trial Results For
This FDA-Approved Treatment Option.
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- How This Treatment Works
Search results
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 days agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoAccording to the results, 16.7% of response-evaluable patients experienced clinical benefits from...
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)
Guru Focus· 6 days agoInc (EXEL, Financial), executed a sale of 27,280 shares of the company. Following this transaction, the insider now owns 5,445 shares of Exelixis Inc. Exelixis Inc is a biotechnology company ...
Kidney Cancer Immunotherapy Response Linked to Signature Reflecting HLA, Tumor Immune Activity
GenomeWeb News· 5 days agoResearchers found an immune checkpoint blockade response signature in renal cell carcinoma that reflects tumor immune activity influenced by human leukocyte antigen features.
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 4 days agoThe company also has other high-impact clinical programs in later stages of development which are intended to treat conditions like renal cell ...
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 7 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 4 days agoPer BMY, this is the first phase III study of the subcutaneous formulation of nivolumab to evaluate...
Aster Insights, ORIEN to Present Research Abstracts at the 60th ASCO Annual Meeting
Valley City Times Record· 5 days agoAster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced the company and members of the Oncology Research Information Exchange Network ...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
WKBN 27 Youngstown· 3 days agoOn May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 4 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
Ads
related to: Renal Cell Carcinoma